

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2024 March 28; 30(12): 1644-1779



**EDITORIAL**

- 1644 Interaction between diet and genetics in patients with inflammatory bowel disease  
*Magro DO, Sasaki LY, Chebli JMF*
- 1651 Pediatric stricturing Crohn's disease  
*Boscarelli A, Bramuzzo M*
- 1655 Gut microbiota and female health  
*Wang MY, Sang LX, Sun SY*
- 1663 Multiparametric ultrasound as a new concept of assessment of liver tissue damage  
*Peltec A, Sporea I*
- 1670 Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope  
*Giri S, Sahoo J*

**OPINION REVIEW**

- 1676 New direction for surgery: Super minimally invasive surgery  
*Linghu EQ*

**REVIEW**

- 1680 Liquid biopsy for gastric cancer: Techniques, applications, and future directions  
*Díaz del Arco C, Fernández Aceñero MJ, Ortega Medina L*

**MINIREVIEWS**

- 1706 Endoscopic treatment of scarred polyps with a non-thermal device (Endorotor): A review of the literature  
*Zaghloul M, Rehman H, Sansone S, Argyriou K, Parra-Blanco A*

**ORIGINAL ARTICLE****Retrospective Study**

- 1714 Predictive value of red blood cell distribution width and hematocrit for short-term outcomes and prognosis in colorectal cancer patients undergoing radical surgery  
*Peng D, Li ZW, Liu F, Liu XR, Wang CY*
- 1727 Assessing recent recurrence after hepatectomy for hepatitis B-related hepatocellular carcinoma by a predictive model based on sarcopenia  
*Peng H, Lei SY, Fan W, Dai Y, Zhang Y, Chen G, Xiong TT, Liu TZ, Huang Y, Wang XF, Xu JH, Luo XH*

- 1739 Treatment patterns and survival outcomes in patients with non-metastatic early-onset pancreatic cancer

*Zhang LT, Zhang Y, Cao BY, Wu CC, Wang J*

**Clinical Trials Study**

- 1751 Early proactive monitoring of DNA-thioguanine in patients with Crohn's disease predicts thiopurine-induced late leucopenia in NUDT15/TPMT normal metabolizers

*Yang T, Chao K, Zhu X, Wang XD, Chan S, Guan YP, Mao J, Li P, Guan SX, Xie W, Gao X, Huang M*

**Basic Study**

- 1764 *ALKBH5* suppresses autophagic flux *via* N6-methyladenosine demethylation of *ZKSCAN3* mRNA in acute pancreatitis

*Zhang T, Zhu S, Huang GW*

**LETTER TO THE EDITOR**

- 1777 Hepatic recompensation according to Baveno VII criteria *via* transjugular intrahepatic portosystemic shunt

*Shaaban HE, Abdellatef A, Okasha HH*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastroenterology*, Tamara Vorobjova, PhD, Academic Research, Associate Professor, Department of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu 51014, Estonia. tamara.vorobjova@ut.ee

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastroenterology* (*WJG*, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. *WJG* mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

**INDEXING/ABSTRACTING**

The *WJG* is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJG* as 4.3; Quartile category: Q2. The *WJG*'s CiteScore for 2021 is 8.3.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Yu-Xi Chen*; Production Department Director: *Xiang Li*; Cover Editor: *Jia-Ru Fan*.

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

Andrzej S Tarnawski

**EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF**

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

**PUBLICATION DATE**

March 28, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**PUBLISHING PARTNER**

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University  
Biliary Tract Disease Institute, Fudan University

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/gerinfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/gerinfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**POLICY OF CO-AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/310>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/gerinfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

**PUBLISHING PARTNER'S OFFICIAL WEBSITE**

<https://www.shca.org.cn>  
<https://www.zs-hospital.sh.cn>

## Interaction between diet and genetics in patients with inflammatory bowel disease

Daniéla Oliveira Magro, Ligia Yukie Sasaki, Júlio Maria Fonseca Chebli

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Rotondo JC, Italy;  
Zhang XN, China

**Received:** November 25, 2023

**Peer-review started:** November 25, 2023

**First decision:** January 19, 2024

**Revised:** January 30, 2024

**Accepted:** February 29, 2024

**Article in press:** February 29, 2024

**Published online:** March 28, 2024



**Daniéla Oliveira Magro**, Department of Surgery, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas 13083-970, São Paulo, Brazil

**Ligia Yukie Sasaki**, Department of Internal Medicine, Medical School, Sao Paulo State University (UNESP), Botucatu 18618-687, São Paulo, Brazil

**Júlio Maria Fonseca Chebli**, Department of Medicine, University Hospital of the Federal University of Juiz de Fora, University of Juiz de Fora School of Medicine, Juiz de Fora 36036-247, Minas Gerais, Brazil

**Corresponding author:** Júlio Maria Fonseca Chebli, MD, PhD, Full Professor, Department of Medicine, University Hospital of the Federal University of Juiz de Fora, University of Juiz de Fora School of Medicine, Rua Maria Jose Leal, 296, Juiz de Fora 36036-247, Minas Gerais, Brazil. [julio.chebli@medicina.ufjf.br](mailto:julio.chebli@medicina.ufjf.br)

### Abstract

In this editorial, we comment on the article by Marangoni *et al*, published in the recent issue of the *World Journal of Gastroenterology* 2023; 29: 5618-5629, about "Diet as an epigenetic factor in inflammatory bowel disease". The authors emphasized the role of diet, especially the interaction with genetics, in promoting the inflammatory process in inflammatory bowel disease (IBD) patients, focusing on DNA methylation, histone modifications, and the influence of microRNAs. In this editorial, we explore the interaction between genetics, gut microbiota, and diet, in an only way. Furthermore, we provided dietary recommendations for patients with IBD. The Western diet, characterized by a low fiber content and deficiency the micronutrients, impacts short-chain fatty acids production and may be related to the pathogenesis of IBD. On the other hand, the consumption of the Mediterranean diet and dietary fibers are associated with reduced risk of IBD flares, particularly in Crohn's disease (CD) patients. According to the dietary guidance from the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD), the regular consumption of fruits and vegetables while reducing the consumption of saturated, trans, dairy fat, additives, processed foods rich in maltodextrins, and artificial sweeteners containing sucralose or saccharine is recommended to CD patients. For patients with ulcerative colitis, the IOIBD recommends the increased intake of natural sources of omega-3 fatty acids and follows the same restrictive recommendations aimed at CD patients, with the possible inclusion of red meats. In conclusion, IBD is a complex and heterogeneous disease, and future studies are needed to elucidate the influence of

epigenetics on diet and microbiota in IBD patients.

**Key Words:** Diet; Genetics; MicroRNAs; Gastrointestinal microbiome; Inflammatory bowel diseases; Crohn's disease

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Diet-related issues are one of the main concerns that inflammatory bowel disease (IBD) patients bring to their clinicians and dietitians and are known to place a substantial burden on patients' quality of life. In this article, we discuss the interaction between diet and genetic factors such as microRNAs and the importance of diet in IBD patients. Furthermore, we provide dietary recommendations for patients during IBD flare as well as healthy nutritional guidelines to be followed during disease remission based on unprocessed or minimally processed foods.

**Citation:** Magro DO, Sasaki LY, Chebli JMF. Interaction between diet and genetics in patients with inflammatory bowel disease. *World J Gastroenterol* 2024; 30(12): 1644-1650

**URL:** <https://www.wjgnet.com/1007-9327/full/v30/i12/1644.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v30.i12.1644>

## INTRODUCTION

In this editorial, we comment on the article by Marangoni *et al*[1], published in the recent issue of the *World Journal of Gastroenterology* about "Diet as an epigenetic factor in inflammatory bowel disease". In this review, the authors discuss the role of epigenetics in the pathogenesis of inflammatory bowel disease (IBD) and its modifications through diet as a mechanism for modulating the intestinal microbiota and attenuating the inflammatory process.

The term epigenetic was studied in the middle of the 19<sup>th</sup> century by biologist British Conrad Hall Waddington[2], to describe the interaction between genes and environment that allows the emergence of phenotypes. The first publication about epigenetics and IBD was in 1996[3]. In patients with IBD, the most studied modifications have been DNA-methylation and noncoding RNA that may be induced by smoking and diet[4,5]. Interestingly, this DNA-methylation is a process that is dependent on cofactors dietary such as substrates and nutrients (folate, vitamins B12, D, and others)[2] and is associated with inflammation, microbiota composition, and microRNAs (miRNAs) which can affect IBD by interfering with T cells differentiation[6]. Marangoni *et al*[1] provided an elegant review of the role of DNA methylation in IBD and its consequences to the inflammatory process.

In the recent review, Natasha and Zilbauer[2] claim that genetic changes may account for modest percentages of IBD, while epigenetic factors could potentially have contributed to the increase in the incidence of disease in recent decades and could be a key role of environmental factors in IBD pathogenesis.

It is worth highlighting that factors determining the degree of cellular epigenetic changes include the type of environmental factors and duration[2]. Some authors consider three critical periods during which the environment may favor the onset of the IBD: In utero, or the early postnatal phase (during gut microbiota colonization), and just before the disease onset[2,7]. Some data suggest that epigenomic reprogramming happens in response to maternal diet modifications, an excess of prenatal micronutrient supplementation (folate, methionine, betaine, and vitamin B12), maternal infection during prenatal, that increase interleukin-6 cytokine and induce epigenetic changes in fetal intestinal, and maternal smoking[7]. These factors could impact the development of IBD in infants.

Therefore, several nutrients present in the diet influence epigenetic modifications. In this way, phenotypic characteristics could be altered through changes in lifestyle and the environment in which the individual lives[3]. The Western diet, characterized by a low fiber content and deficiency of the micronutrients[5], impacts the short-chain fatty acids (SCFAs) levels and can induce epigenetic changes related to IBD, with the decrease in miR-143/145a, miR-148a, and miR-152 in colonocytes[7].

The inhibition of SCFA production (acetate, butyrate, and propionate) due to the low-fiber diet appears to play a critical role in the epigenetic control of the inflammation[5]. SCFA are essential for epithelial cell homeostasis and can epigenetically regulate the immune response and induce intracellular signaling pathways through the activation of G-protein coupled receptors[8].

The high-fat diet or diet rich in n-6 linoleic acid, particularly arachidonic acid, or high sugar diet have a proinflammatory activity that can change the miRNA profile of the visceral adipose exosomes or DNA methylation respectively, resulting in gut microbiota dysbiosis, dysregulating gut immune homeostasis, and increasing the risk of inflammation[5, 7]. In the same way, the chronic alcohol consumption increases miR-122 and miR155 expression in the intestine and decreases occludin expression, leading to increased intestinal permeability[7].

Of note, the microbiome may induce epigenetic changes both in the intestinal epithelium and in immune cells[7]. Species bacteria such as *Faecalibacterium Prausnitzii*, *Roseburia* (Phylum Firmicutes), and *Bacteroides* genera, have anti-inflammatory action and are reduced in IBD while Proteobacteria (*Enterobacteriaceae* and *Bilophila*) are increased[8]. The bacteria commensal concerns the bioavailability of methyl groups through their production of folate and affects the host DNA methylation[7]. Many studies support that diet may change genome expression and induce host epigenetic

modification stably changing DNA structure[3].

Notably, lipopolysaccharides, a major component of bacteria Gram-negative[9], also play an important role in the epigenetics of IBD, as it has pro-inflammatory activity, increasing inflammatory cytokines[7] and the intestinal permeability[8].

Furthermore, the interaction between miRNA and gut microbiota in IBD patients has been emphasized by recent studies[10,11]. However, the exact mechanisms through which miRNAs are involved in IBD or dysbiosis are still unexplored. It is hypothesized that miRNAs could act as physiological regulators of the inflammatory process more than it participate in the inflammatory pathogenesis[12]. Intestinal miRNAs can interact with host microbiota and alter the growth and composition of bacterial gene expression[12]. On the other hand, gut microbiota can conversely regulate the expression of miRNA[13], altering the host status and predisposing to diseases. Some examples are the influence of gut microbiota on fecal miRNAs let-7, and miR-148, which target Enterobacteriaceae and Proteobacteria, respectively, and miR-21, which increases the abundance of IBD-related Bacteroidetes phylum and reduces the abundance of protective Firmicutes and Clostridia phylum[13]. In conclusion, the dysregulation of miRNAs could cause microbiota changes, leading to intestinal epithelial dysfunction, and immune hyperactivation[14]. Despite the recent findings, the complex relationship between intestinal microbiota and miRNAs in IBD deserves more attention.

In addition to miRNA, the role of circular RNA (circRNAs) in IBD has also been studied. CircRNAs are noncoding RNAs with covalently closed loop structures[15]. CircRNAs are involved in various diseases such as metabolic disorders [16], cardiovascular diseases[17], cancer[18] and IBD[19], showing their potential role as biomarkers for diagnosis, prognosis, or even as therapeutic targets for IBD. CircRNAs act together with miRNA in various inflammatory process, acting as miRNA sponges and altering their expression, and interacting with proteins[19]. Changes in the expression of circRNAs can impair the intestinal epithelial barrier and intestinal epithelium homeostasis[19], as demonstrated that depletion of circPan3 in human inhibited the renewal of intestinal stem cells, leading to the inhibition of epithelium regeneration[20]. A list of circRNAs has been associated with IBC, both Crohn's disease (CD) or ulcerative colitis (UC), all related to the intestinal epithelium and inflammatory process, and some are overexpressed (Circ\_0001187; CircRNA\_103765; CircRNA\_102610; CircRNA\_103516; CircRNA\_102685; CircAtp9b; CircRNA\_004662; CircSMAD4; CircKcnt2; CircZbtb20) while others are under expressed (CircHECTD1; CircHIPK3; CircGMCL1; Circ\_CCND1; CircCDKN2BAS1; Circ\_0007919; Circ\_0001021)[19]. Despite this, circRNAs are not well characterized, and more in-depth studies are necessary to elucidate its role and applications in clinical practice for IBD patients.

Despite the need for greater elucidation on the role of the interaction between genetics and microbiota in the inflammatory activity of patients with IBD, it is worth highlighting that nutritional therapy is a safe and non-invasive treatment for IBD, by altering the gut microbiota and increases the production of SCFA, which appears to play a critical role in the epigenetic control of the inflammatory response[5].

## DIETARY TIPS FOR PATIENTS WITH IBD

Diet-related issues are one of the main concerns that IBD patients bring to their clinicians and are known to place a substantial burden on patients' quality of life.

Every clinician who focuses their practice on IBD patient management is faced with situations where the patient with IBD requests recommendations on what types of foods he/she should avoid or consume since it is not uncommon for the patient to believe and report that certain foods seem to exacerbate his disease. It is important to emphasize that dietary manipulations must be tempered in these settings since there are some risks of restrictive diets in this nutritionally challenged population. Indeed, malnutrition in the IBD population already is high. In addition, many of these patients already have wrong beliefs about diet and adopt a series of food or food group restrictions such as a gluten-free diet, and paleo and vegan diets, which increases the risk of malnutrition. Thus, it's always important to work with a dietitian skilled in IBD management.

While it is well accepted that diet is one of the main modulators of the gut microbiota, thought to play a crucial and causative role in IBD, currently, there are no widely accepted evidence-based dietary approaches for managing patients with IBD[21-23]. In certain clinical contexts, some dietary tips are beneficial and important to emphasize. For example, a Mediterranean diet rich in a variety of fresh fruits and vegetables, monounsaturated fats, complex carbohydrates, and lean proteins, and low in ultra processed foods, added sugar, and salt[23] is recommended for all patients with IBD, a low-residue or fiber diet (avoiding, especially leafy green vegetables, nuts, seeds, beans, and kernels) for CD patients with symptomatic strictures to avoid bowel obstruction, a low FODMAP diet for patients with functional gut symptoms in association with quiescent IBD, or a low-fat diet for bile acid diarrhea after ileocecal resection, and an increased intake of fluids and calcium and reduced intake of oxalate-rich foods for those patients with kidney stones[22,23].

In the meantime, what dietary recommendations could a clinician caring for patients with IBD offer to their patients in daily clinical practice?

Despite the time-honored axiom "you are what you eat", no specific diet or nutritional intervention has been shown to prevent or treat IBD, except for the use of exclusive enteral nutrition as induction therapy for pediatric CD and the Crohn disease exclusion diet (CDED) for adults CD[5,24]. Regardless of this fact, some diet strategies help control symptoms. Based on experience in clinical practice in IBD, some dietary strategies for managing symptoms during flares can be recommended (Table 1).

Conversely, a wide range of recent studies have evaluated the relationship between ultra-processed food consumption (UPF) and IBD pathogenesis and have systematically shown a strong association between higher levels of consumption of UPFs and an increased risk of being newly diagnosed with CD[25,26]. UPF components, such as emulsifiers, thickeners,

**Table 1** Tips for dietary adjustments during flares of inflammatory bowel disease[5,9,22,25-27,29]

No.	Tips
1	Avoid foods that may exacerbate diarrhea such as raw vegetables, fresh fruits with peel, prunes, spicy foods, fried or greasy foods, concentrated sweets, and caffeinated beverages
2	Avoid ultra-processed food
3	Prefer smaller, more frequent meals that are better tolerated and can increase calories and nutrient intake
4	Try to incorporate into your feed that constitutes the nutritional basis of the Mediterranean diet
5	Follow a lactose-free diet because it is not uncommon to develop transient lactose deficiency during flares
6	Avoid alcoholic drinks
7	Consider using nutritional supplements if solid foods are not well tolerated during the flare or your appetite is much reduced
8	Consider the use of EEN or CDED (PEN + modified oral diet) for Crohn disease according to the patient's tolerances

CDED: Crohn's disease exclusion diet; PEN: Partial enteral nutrition; EEN: Exclusive enteral nutrition.

salt, artificial sweeteners, phosphate, and food colorants (titanium dioxide, Azo dyes) can negatively affect the intestinal barrier, inducing dysbiosis, affecting the mucus layer, increasing the permeability of the intestinal epithelium, or directly interacting with the immune system[25,27].

Additionally, cumulative evidence suggests that a Mediterranean diet and a specific carbohydrate diet may help induce clinical remission in patients with CD, although this issue is still debated[23,28,29]. Indeed, in a recent randomized trial, researchers compared the consumption of a Mediterranean-style diet to the consumption of the specific carbohydrate diet for 12 wk in adult patients with CD who presented mild to moderate activity[30]. After 6 wk of following these 2 different diets, researchers found similar rates of symptomatic remission (46.5% *vs* 43.5% for the specific carbohydrate diet and Mediterranean diet, respectively;  $P = 0.77$ ). Similarly, a reduction in fecal calprotectin levels was achieved in 34.8% with the specific carbohydrate diet and in 30.8% with the Mediterranean diet ( $P = 0.83$ ). While the specific carbohydrate diet has some evidence that it can be beneficial for patients with CD, this trial was not able to show that it was better than the Mediterranean diet. For the practicing clinician, this finding has fundamental importance: The Mediterranean-style diet is less complex for patients to adopt in their busy lives compared to the specific carbohydrate diet. Moreover, this diet has the potential to bring several health benefits, including cardiovascular health outside of its favorable effects on CD patients[31].

Notably, maintenance dietary strategies in IBD lack evidence, except for the Mediterranean diet and consumption of dietary fibers which are associated with reduced risk of IBD flares, particularly CD[32]. Interestingly, some preclinical data suggest that a Westernized diet rich in saturated fat, refined carbohydrates, proteins from meat, processed foods and food additives influence the abundance, colonization, and phenotypic behavior of *Escherichia coli* in the gut, which may in turn initiate or contribute to gut inflammation. Conversely, the Mediterranean diet and specific dietary fibers may decrease *Escherichia coli* colonization and protect from invasion and adherence and consequently intestinal inflammation [33]. Moreover, from an epidemiological point of view, a Westernized diet that includes low consumption of fiber, fruit, and vegetables, has been shown to have pro-inflammatory effects and has been associated with a wide range of immune-mediated conditions, including a higher prevalence of IBD[34]. Regrettably, the Mediterranean diet has an important limiting factor, that is, its high cost, which can make access difficult in low-income countries.

Hopefully, future studies will be able to better determine the putative interrelationship between the consumption of specific food products, or their constituents, intestinal microbiome, and epigenetic mechanisms in IBD to target these factors in managing IBD. While we await the results of these studies, at present, some dietary tips that can be easily adopted by IBD patients in their busy daily lives can be appropriate, including consuming a well-balanced diet consisting mainly of fresh ingredients such as fruits, vegetables, legumes, whole grains, lean protein, olive oil, fish, limited red meat, and low-fat and nonfat dairy products, while avoiding processed meats, UPFs, food additives and emulsifiers[35-37]. Endorsing these dietary tips recent dietary guidance from the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) based on the best available evidence to date recommends that CD patients engage in regular consumption of fruits and vegetables while reducing the consumption of saturated, trans, dairy fat, additives, processed dairy or foods rich in maltodextrins, artificial sweeteners containing sucralose or saccharine, and processed food containing nanoparticles[37]. For patients with UC, the IOIBD recommends the increased intake of natural sources of omega-3 fatty acids (for instance, from oil olive, wild salmon, and other natural sources, not from supplements). Likewise, the types of food that patients with UC should avoid are similar to CD with the possible inclusion of red meats [37]. Ultimately, well-designed randomized controlled clinical trials are required before evidence-based dietary recommendations for IBD management can be made. It is also plausible that in the future personalized dietary strategies for each patient could be implemented based on better knowledge of the interaction between nutrients, gut microbiome and metabolome, and individual genetics.

## ADVANTAGES AND LIMITATIONS OF EPIGENOME STUDIES

Epigenome-wide association studies brought advantages such as (1) finding novel methylation sites associated with disease; (2) evaluating the environmental impact of genetic regulation; and (3) explaining part of the heritability missed out by genome-wide association analysis. On the other hand, there are still gaps such as (1) expansion of sample size and ethnic diversity; (2) existence of the heterogeneity of sample material; and (3) causal inference of the identified epigenetic is challenging[6].

The complexity and heterogeneity of IBD make it a challenge because it is an evolving disease, and one treatment will not suit all patients. It is believed that precision medicine is the future for the treatment of IBD and among the studies and databases, epigenetics is included. Future perspectives are needed to elucidate the influence of epigenetics on diet and microbiota in IBD patients.

## CONCLUSION

Diet is thought to play a role in the pathogenesis of IBD and may contribute to triggering IBD flares. In particular, some dietary components may interact with gut microbiota and genetics to trigger or perpetuate intestinal inflammation. Patients with IBD often requests recommendations on what types of foods he/she should avoid or consume, since it is not uncommon for the patient to associate their diet with symptoms. Briefly, cumulative evidence strongly suggests that higher levels of consumption of UPFs increase the risk of CD. A diet low in UPFs could encourage induced remission or control of symptoms in patients with IBD. Conversely, a healthier or Mediterranean-style diet is likely to be protective for CD development. From a therapeutic point of view, the specific carbohydrate diet, CDED, or a Mediterranean-style diet may be beneficial for the treatment of patients with CD who have mild to moderate symptoms. A diet low in red and processed meat may reduce the risk of flares in UC. In addition, a low FODMAP diet is beneficial for patients with functional gut symptoms in association with quiescent IBD. For patients with IBD in remission, the consumption of the Mediterranean diet and dietary fibers as adjunctive therapies may be recommended to reduce the risk of IBD flares, particularly in CD patients. For patients with UC, the increased intake of natural sources of omega-3 fatty acids and the following of restrictive recommendations aimed at CD patients may be useful in reducing UC flare-ups. All patients with IBD should be monitored for malnutrition, vitamin D, and iron deficiency and, in some situations, for vitamin B12 deficiency.

## FOOTNOTES

**Author contributions:** Magro DO, Sasaki LY, and Chebli JMF contributed to the conception and design of the study, acquisition of data, drafting of the article, and making critical revisions related to the important intellectual content of the manuscript. All the authors approved the final version of the article to be published.

**Conflict-of-interest statement:** The author declares no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** Brazil

**ORCID number:** Daniéla Oliveira Magro 0000-0002-8180-6254; Lígia Yukie Sasaki 0000-0002-7319-8906; Júlio Maria Fonseca Chebli 0000-0003-1527-0663.

**S-Editor:** Fan JR

**L-Editor:** A

**P-Editor:** Cai YX

## REFERENCES

- 1 Marangoni K, Dorneles G, da Silva DM, Pinto LP, Rossoni C, Fernandes SA. Diet as an epigenetic factor in inflammatory bowel disease. *World J Gastroenterol* 2023; **29**: 5618-5629 [DOI: [10.3748/wjg.v29.i41.5618](https://doi.org/10.3748/wjg.v29.i41.5618)]
- 2 Natasha G, Zilbauer M. Epigenetics in IBD: a conceptual framework for disease pathogenesis. *Frontline Gastroenterol* 2022; **13**: e22-e27 [PMID: [35812027](https://pubmed.ncbi.nlm.nih.gov/35812027/) DOI: [10.1136/flgastro-2022-102120](https://doi.org/10.1136/flgastro-2022-102120)]
- 3 Xu J, Xu HM, Yang MF, Liang YJ, Peng QZ, Zhang Y, Tian CM, Wang LS, Yao J, Nie YQ, Li DF. New Insights Into the Epigenetic Regulation of Inflammatory Bowel Disease. *Front Pharmacol* 2022; **13**: 813659 [PMID: [35173618](https://pubmed.ncbi.nlm.nih.gov/35173618/) DOI: [10.3389/fphar.2022.813659](https://doi.org/10.3389/fphar.2022.813659)]
- 4 Annese V. Genetics and epigenetics of IBD. *Pharmacol Res* 2020; **159**: 104892 [PMID: [32464322](https://pubmed.ncbi.nlm.nih.gov/32464322/) DOI: [10.1016/j.phrs.2020.104892](https://doi.org/10.1016/j.phrs.2020.104892)]
- 5 Castro F, de Souza HSP. Dietary Composition and Effects in Inflammatory Bowel Disease. *Nutrients* 2019; **11** [PMID: [31234325](https://pubmed.ncbi.nlm.nih.gov/31234325/) DOI: [10.3390/11050892](https://doi.org/10.3390/11050892)]

- 10.3390/nu11061398]
- 6 **Mu C**, Zhao Q, Yang L, Pang X, Liu T, Li X, Wang B, Fung SY, Cao H. Multi-omics in Crohn's disease: New insights from inside. *Comput Struct Biotechnol J* 2023; **21**: 3054-3072 [PMID: 37273853 DOI: 10.1016/j.csbj.2023.05.010]
  - 7 **Vieujean S**, Caron B, Haghnejad V, Jouzeau JY, Netter P, Heba AC, Ndiaye NC, Moulin D, Barreto G, Danese S, Peyrin-Biroulet L. Impact of the Exposome on the Epigenome in Inflammatory Bowel Disease Patients and Animal Models. *Int J Mol Sci* 2022; **23** [PMID: 35886959 DOI: 10.3390/ijms231476111]
  - 8 **Santana PT**, Rosas SLB, Ribeiro BE, Marinho Y, de Souza HSP. Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets. *Int J Mol Sci* 2022; **23** [PMID: 35408838 DOI: 10.3390/ijms23073464]
  - 9 **Magro DO**, Kotze PG, Martinez CAR, Camargo MG, Guadagnini D, Calixto AR, Vasques ACJ, Ayrizono MLS, Geloneze B, Pareja JC, Saad MJ, Coy CSR. Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease. *Intest Res* 2017; **15**: 352-357 [PMID: 28670232 DOI: 10.5217/ir.2017.15.3.352]
  - 10 **Casado-Bedmar M**, Viennois E. MicroRNA and Gut Microbiota: Tiny but Mighty-Novel Insights into Their Cross-talk in Inflammatory Bowel Disease Pathogenesis and Therapeutics. *J Crohns Colitis* 2022; **16**: 992-1005 [PMID: 34918052 DOI: 10.1093/ecco-jcc/ijab223]
  - 11 **Oliveira ECS**, Quaglio AEV, Magro DO, Di Stasi LC, Sasaki LY. Intestinal Microbiota and miRNA in IBD: A Narrative Review about Discoveries and Perspectives for the Future. *Int J Mol Sci* 2023; **24** [PMID: 37108339 DOI: 10.3390/ijms24087176]
  - 12 **Yuan C**, Steer CJ, Subramanian S. Host-MicroRNA-Microbiota Interactions in Colorectal Cancer. *Genes (Basel)* 2019; **10** [PMID: 30987065 DOI: 10.3390/genes10040270]
  - 13 **Viennois E**, Chassaing B, Tahsin A, Pujada A, Wang L, Gewirtz AT, Merlin D. Host-derived fecal microRNAs can indicate gut microbiota healthiness and ability to induce inflammation. *Theranostics* 2019; **9**: 4542-4557 [PMID: 31285778 DOI: 10.7150/thno.35282]
  - 14 **Wu LY**, Ma XP, Shi Y, Bao CH, Jin XM, Lu Y, Zhao JM, Zhou CL, Chen D, Liu HR. Alterations in microRNA expression profiles in inflamed and noninflamed ascending colon mucosae of patients with active Crohn's disease. *J Gastroenterol Hepatol* 2017; **32**: 1706-1715 [PMID: 28261881 DOI: 10.1111/jgh.13778]
  - 15 **Liu CX**, Chen LL. Circular RNAs: Characterization, cellular roles, and applications. *Cell* 2022; **185**: 2016-2034 [PMID: 35584701 DOI: 10.1016/j.cell.2022.04.021]
  - 16 **Fan W**, Pang H, Xie Z, Huang G, Zhou Z. Circular RNAs in diabetes mellitus and its complications. *Front Endocrinol (Lausanne)* 2022; **13**: 885650 [PMID: 35979435 DOI: 10.3389/fendo.2022.885650]
  - 17 **Aufiero S**, Reckman YJ, Pinto YM, Creemers EE. Circular RNAs open a new chapter in cardiovascular biology. *Nat Rev Cardiol* 2019; **16**: 503-514 [PMID: 30952956 DOI: 10.1038/s41569-019-0185-2]
  - 18 **Feng Z**, Li L, Tu Y, Shu X, Zhang Y, Zeng Q, Luo L, Wu A, Chen W, Cao Y, Li Z. Identification of Circular RNA-Based Immunomodulatory Networks in Colorectal Cancer. *Front Oncol* 2021; **11**: 779706 [PMID: 35155186 DOI: 10.3389/fonc.2021.779706]
  - 19 **Lun J**, Guo J, Yu M, Zhang H, Fang J. Circular RNAs in inflammatory bowel disease. *Front Immunol* 2023; **14**: 1307985 [PMID: 38187401 DOI: 10.3389/fimmu.2023.1307985]
  - 20 **Zhu P**, Zhu X, Wu J, He L, Lu T, Wang Y, Liu B, Ye B, Sun L, Fan D, Wang J, Yang L, Qin X, Du Y, Li C, Ren W, Wu X, Tian Y, Fan Z. IL-13 secreted by ILC2s promotes the self-renewal of intestinal stem cells through circular RNA circPan3. *Nat Immunol* 2019; **20**: 183-194 [PMID: 30643264 DOI: 10.1038/s41590-018-0297-6]
  - 21 **Sabino J**, Torres J. You Are What You Eat, But Can Diet Prevent Inflammatory Bowel Diseases? *Gastroenterology* 2020; **158**: 2304-2305 [PMID: 32315670 DOI: 10.1053/j.gastro.2020.04.035]
  - 22 **Fitzpatrick JA**, Melton SL, Yao CK, Gibson PR, Halmos EP. Dietary management of adults with IBD - the emerging role of dietary therapy. *Nat Rev Gastroenterol Hepatol* 2022; **19**: 652-669 [PMID: 35577903 DOI: 10.1038/s41575-022-00619-5]
  - 23 **Hashash JG**, Elkins J, Lewis JD, Binion DG. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review. *Gastroenterology* 2024; **166**: 521-532 [PMID: 38276922 DOI: 10.1053/j.gastro.2023.11.303]
  - 24 **Yanai H**, Levine A, Hirsch A, Boneh RS, Kopylov U, Eran HB, Cohen NA, Ron Y, Goren I, Leibovitz H, Wardi J, Zittan E, Ziv-Baran T, Abramson L, Fliss-Isakov N, Raykhel B, Gik TP, Dotan I, Maharshak N. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. *Lancet Gastroenterol Hepatol* 2022; **7**: 49-59 [PMID: 34739863 DOI: 10.1016/S2468-1253(21)00299-5]
  - 25 **Chen J**, Wellens J, Kalla R, Fu T, Deng M, Zhang H, Yuan S, Wang X, Theodoratou E, Li X, Satsangi J. Intake of Ultra-processed Foods Is Associated with an Increased Risk of Crohn's Disease: A Cross-sectional and Prospective Analysis of 187 154 Participants in the UK Biobank. *J Crohns Colitis* 2023; **17**: 535-552 [PMID: 36305857 DOI: 10.1093/ecco-jcc/ijac167]
  - 26 **Narula N**, Chang NH, Mohammad D, Wong ECL, Ananthakrishnan AN, Chan SSM, Carbonnel F, Meyer A. Food Processing and Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. *Clin Gastroenterol Hepatol* 2023; **21**: 2483-2495.e1 [PMID: 36731590 DOI: 10.1016/j.cgh.2023.01.012]
  - 27 **Vissers E**, Wellens J, Sabino J. Ultra-processed foods as a possible culprit for the rising prevalence of inflammatory bowel diseases. *Front Med (Lausanne)* 2022; **9**: 1058373 [PMID: 36419796 DOI: 10.3389/fmed.2022.1058373]
  - 28 **Limketkai BN**, Godoy-Brewer G, Parian AM, Noorian S, Krishna M, Shah ND, White J, Mullin GE. Dietary Interventions for the Treatment of Inflammatory Bowel Diseases: An Updated Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2023; **21**: 2508-2525.e10 [PMID: 36470529 DOI: 10.1016/j.cgh.2022.11.026]
  - 29 **Cusimano FA**, Damas OM. Diet as a treatment for inflammatory bowel disease: is it ready for prime time? *Curr Opin Gastroenterol* 2022; **38**: 358-372 [PMID: 35762695 DOI: 10.1097/MOG.0000000000000850]
  - 30 **Lewis JD**, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF, Hanson JS, Suskind DL, Meyer A, Compher CW, Bewtra M, Saxena A, Dobes A, Cohen BL, Flynn AD, Fischer M, Saha S, Swaminath A, Yacyshyn B, Scherl E, Horst S, Curtis JR, Braly K, Nessel L, McCauley M, McKeever L, Herfarth H, DINE-CD Study Group. A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. *Gastroenterology* 2021; **161**: 837-852.e9 [PMID: 34052278 DOI: 10.1053/j.gastro.2021.05.047]
  - 31 **Martínez-González MA**, Gea A, Ruiz-Canela M. The Mediterranean Diet and Cardiovascular Health. *Circ Res* 2019; **124**: 779-798 [PMID: 30817261 DOI: 10.1161/CIRCRESAHA.118.313348]
  - 32 **Brotherton CS**, Martin CA, Long MD, Kappelman MD, Sandler RS. Avoidance of Fiber Is Associated With Greater Risk of Crohn's Disease Flare in a 6-Month Period. *Clin Gastroenterol Hepatol* 2016; **14**: 1130-1136 [PMID: 26748217 DOI: 10.1016/j.cgh.2015.12.029]
  - 33 **Faqerah N**, Walker D, Gerasimidis K. Review article: The complex interplay between diet and Escherichia coli in inflammatory bowel

- disease. *Aliment Pharmacol Ther* 2023; **58**: 984-1004 [PMID: 37771255 DOI: 10.1111/apt.17720]
- 34 **Rizzello F**, Spisni E, Giovanardi E, Imbesi V, Salice M, Alvisi P, Valerii MC, Gionchetti P. Implications of the Westernized Diet in the Onset and Progression of IBD. *Nutrients* 2019; **11** [PMID: 31072001 DOI: 10.3390/nu11051033]
- 35 **Brown AC**, Rampertab SD, Mullin GE. Existing dietary guidelines for Crohn's disease and ulcerative colitis. *Expert Rev Gastroenterol Hepatol* 2011; **5**: 411-425 [PMID: 21651358 DOI: 10.1586/egh.11.29]
- 36 **Sabino J**, Lewis JD, Colombel JF. Treating Inflammatory Bowel Disease With Diet: A Taste Test. *Gastroenterology* 2019; **157**: 295-297 [PMID: 31254503 DOI: 10.1053/j.gastro.2019.06.027]
- 37 **Levine A**, Rhodes JM, Lindsay JO, Abreu MT, Kamm MA, Gibson PR, Gasche C, Silverberg MS, Mahadevan U, Boneh RS, Wine E, Damas OM, Syme G, Trakman GL, Yao CK, Stockhamer S, Hammami MB, Garces LC, Rogler G, Koutroubakis IE, Ananthakrishnan AN, McKeever L, Lewis JD. Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol* 2020; **18**: 1381-1392 [PMID: 32068150 DOI: 10.1016/j.cgh.2020.01.046]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

